Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

Coleiro, Bernard; Marshall, S.E.; Denton, Chris; Howell, Kevin; Blann, Andrew D.; Welsh, Kenneth I.; Black, CM

doi:10.1093/rheumatology/40.9.1038

Cited by 216 publications

(93 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although some clinical trials on patients with primary or secondary RP using nifedipine have been performed intermittently [16][17][18][19], this study was the first clinical trial using South Korean patients with primary RP as its subjects.…”

Section: Discussionmentioning

confidence: 99%

To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study)

Choi

Kim

et al. 2009

Clin Rheumatol

View full text Add to dashboard Cite

This study examined the efficacy and safety of nifedipine sustained release (nifedipine SR) compared with Ginkgo biloba extract as treatment for primary Raynaud's phenomenon (RP) in Korea. Primary RP were screened and assigned to either the nifedipine SR group (Group N) or the Ginkgo biloba extract group (Group G) in the ratio of 2:1. After a run-in period of 2 weeks, patients received treatment for 8 weeks. We observed the percent improvement of the RP attack rate between before and after the 8-week treatment. Ninety-three subjects were randomly assigned. The percent improvement in Group N was 50.1% at 8 weeks after treatment, while it was 31.0% in Group G (p=0.03). No serious adverse events occurred, and almost adverse events were mild and improved without specific treatment. nifedipine SR was more effective than Ginkgo biloba extract for treatment of primary RP in Korean patients. Both drugs were tolerable with primary RP patients.

show abstract

Section: Discussionmentioning

confidence: 99%

To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study)

Choi

Kim

et al. 2009

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…Some clinicians favour the angiotensin receptor antagonist losartan, which showed benefi t in a head to head open label trial against nifedipine; however, no further studies have yet been published. Fluoxetine [24], an SSRl, was compared to nifedipine in an open-label cross-over study including patients with both primary and secondary RP and conferred benefi t in terms of frequency and severity of attacks. Fluoxetine may be benefi cial in patients intolerant to other therapies which are more likely to cause vasodilatory side eff ects.…”

Section: Drug Treatmentmentioning

confidence: 99%

ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon

Belch

Carlizza

Carpentier

et al. 2017

Vasa

View full text Add to dashboard Cite

Abstract. Regarding the clinical diagnosis of Raynaud’s phenomenon and its associated conditions, investigations and treatment are substantial, and yet no international consensus has been published regarding the medical management of patients presenting with this condition. Most knowledge on this topic derives from epidemiological surveys and observational studies; few randomized studies are available, almost all relating to drug treatment, and thus these guidelines were developed as an expert consensus document to aid in the diagnosis and management of Raynaud’s phenomenon. This consensus document starts with a clarification about the definition and terminology of Raynaud’s phenomenon and covers the differential and aetiological diagnoses as well as the symptomatic treatment.

show abstract

“…Due to the vasoconstrictive properties of serotonin, the selective serotonin reuptake inhibitors (SSRIs) have been suggested to be benefi cial for the treatment of RP. The effects of fl uoxetine were assessed in a cross-over study including 26 primary RP and 27 secondary RP patients [48]. All of the patients received a 6 week treatment course with fl uoxetine 20 mg daily or sustained-release nifedipine 40 mg daily.…”

Section: Other Oral Vasodilatorsmentioning

confidence: 99%

Raynaud’s phenomenon and digital ischaemia - pharmacologic approach and alternative treatment options

Linnemann

Erbe

2016

Vasa

View full text Add to dashboard Cite

Summary:The primary goal of therapy is to reduce the frequency and intensity of Raynaud's attacks and to minimize the related morbidity rather than to cure the underlying condition. Treatment strategies depend on whether Raynaud's phenomenon (RP) is primary or secondary. All patients should be instructed about general measures to maintain body warmth and to avoid triggers of RP attacks. Pharmacologic intervention can be useful for patients with severe and frequent RP episodes that impair the patient's quality of life. Calcium channel blockers are currently the most prescribed and studied medications for this purpose. There has been limited evidence for the effi cacy of alpha-1-adrenergic receptor antagonists, angiotensin receptor blockers, topical nitrates or fl uoxetine to treat RP. The intravenously administered prostacyclin analogue iloprost can reduce the frequency and severity of RP attacks and is considered a second-line therapy in patients with markedly impaired quality of life, critical digital ischaemia and skin ulcers who are at risk for substantial tissue loss and amputation. Phosphodiesterase inhibitors (e.g., sildenafi l) can also improve RP symptoms and ulcer healing whereas endothelin-1 receptor antagonists (e.g., bosentan) are mainly considered treatment options in secondary prevention for patients with digital skin ulcers related to systemic sclerosis. However, their use in clinical practice has been limited by their high cost. Antiplatelet therapy with low-dose aspirin is recommended for all patients who suffer from secondary RP due to ischaemia caused by structural vessel damage. Anticoagulant therapy can be considered during the acute phase of digital ischaemia in patients with suspected vascular occlusive disease attributed to the occurrence of new thromboses. In patients with critical digital ischaemia, consideration should be given to hospitalisation, optimisation of medical treatment in accordance with the underlying disease and evaluation for a secondary, possibly reversible process that is causing or aggravating the clinical symptoms.

show abstract

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

Abstract: This pilot study confirms the tolerability of fluoxetine and suggests that it would be effective as a novel treatment for Raynaud's phenomenon. Larger and placebo-controlled trials are warranted to assess fluoxetine's therapeutic potential further in this vasospastic condition.

Cited by 216 publications

References 17 publications

To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study)

To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study)

ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon

Raynaud’s phenomenon and digital ischaemia - pharmacologic approach and alternative treatment options

Contact Info

Product

Resources

About